Oocyte function recovery preparation for TRIP13 gene mutation induced oocyte maturation defect and use method of oocyte function recovery preparation

Abstract

The invention belongs to the technical field of gene therapy, and particularly relates to an oocyte function recovery preparation for TRIP13 gene mutation induced oocyte maturation defect and a use method of the oocyte function recovery preparation. Clinical manifestations of patients with oocyte maturation defect are that in a test tube baby operation, most of the patients cannot obtain mature oocytes or the mature oocytes are low in fertilization rate and free of effective embryos after excretion promotion, so that test tube babies repeatedly fail. The invention provides the oocyte functionrecovery preparation for CDC20 gene mutation induced oocyte maturation defect. The preparation is prepared from TRIP13cRNA or TRIP13 protein with a certain concentration. The preparation is injected into the oocytes of the patients, so that the oocytes of the patients complete a maturation process or the fertilization rate is remarkably improved, effective embryos can be obtained, and pregnancy isfinally established.

Description

technical field [0001] The invention belongs to the technical field of gene therapy, and in particular relates to an oocyte function recovery preparation for oocyte maturation disorder caused by TRIP13 gene mutation and a use method thereof. Background technique [0002] Mature sperm and egg produce totipotent zygote through normal fertilization, which is the key link of successful human reproduction. Therefore, egg maturation disorder can lead to female infertility and repeated failure of clinical assisted reproduction. Clinically, the phenotype of egg maturation disorder mainly includes that the eggs are never mature or the fertilization rate of mature eggs is low. Patients need to retrieve eggs multiple times to obtain very few effective embryos or despite multiple egg retrievals, they still cannot obtain effective embryos. At present, genes such as TUBB8 and PATL2 have been found to be related to egg maturation disorders. However, these two gene mutations can only expl...

AI Technical Summary

Problems solved by technology

However, these two gene mutations can only explain a very small number of patients with egg maturation disorders. We recently found that TRIP13 mutations exist in multiple patients with egg maturation disorders (Zhang et al. Bi-allelic Missense Pathogenic Variants in TRIP13 Cause Female Infertility Characterized by Oocyte Maturation Arrest . Am J Hum Genet. 2020;107(1):15-23)

In addition, in the current clinical practice of assisted reproduction, there is no method to improve and treat patients with oocyte maturation disorders.

However, there are no reports of gene therapy applied to reproductive diseases